What's Happening?
Biogen and Denali have decided to discontinue the development of their Parkinson's disease drug candidate BIIB122 following disappointing results from a phase 2b trial. The trial, known as LUMA, failed to demonstrate that BIIB122 slowed the progression
of Parkinson's disease compared to a placebo. Despite initial hopes, the drug did not meet primary or secondary endpoints, although it did show some reduction in LRRK2 kinase activity. The decision to halt development comes after an earlier decision to abandon a larger phase 3 study. Denali will continue a separate phase 2a study focusing on patients with specific LRRK2 mutations.
Why It's Important?
The discontinuation of BIIB122 is a setback for Biogen and Denali, who had invested significantly in the development of LRRK2 inhibitors as a potential treatment for Parkinson's disease. The failure of the LUMA trial raises questions about the viability of targeting LRRK2 as a therapeutic approach, impacting other companies pursuing similar strategies. This development underscores the challenges in developing effective treatments for Parkinson's, a disease with significant unmet medical needs. The outcome may influence future research directions and investment decisions in the field of neurodegenerative diseases.
What's Next?
Denali plans to analyze the LUMA data further and continue its BEACON study, which focuses on patients with specific LRRK2 mutations. The results of this study could provide insights into the potential of LRRK2 inhibitors for a subset of Parkinson's patients. Other companies working on LRRK2 inhibitors, such as Neuron23 and Oncodesign Precision Medicine, may need to reassess their development strategies in light of these results. The broader Parkinson's research community will likely monitor these developments closely to inform future therapeutic approaches.
